PMID- 24297035
OWN - NLM
STAT- MEDLINE
DCOM- 20140903
LR  - 20161125
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 31
IP  - 2
DP  - 2014 Feb
TI  - Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.
PG  - 701-6
LID - 10.3892/or.2013.2886 [doi]
AB  - To elucidate the molecular mechanisms underlying the insufficient sensitivity in 
      the detection of hepatocellular carcinoma (HCC) by [18F] 
      2- fl uoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), the 
      characteristics of glucose metabolism-related protein expression in HCC were 
      examined in liver metastasis from colorectal cancer (Meta). Thirty-four patients 
      (14 Meta and 20 HCC) who underwent FDG-PET and hepatectomy were studied. The 
      relationships between the maximum standardized uptake value (SUV) in tumors and 
      the mRNA expression of glucose metabolism-related proteins [hexokinase (HK), 
      glucose transporter 1 (GLUT1), and glucose-6-phosphatase (G6Pase)] and 
      proliferating cell nuclear antigen (PCNA) were examined in snap-frozen specimens 
      with quantitative PCR. Tumor detection rates were lower in HCC (15/20) compared 
      to Meta (13/14) patients. HK and GLUT1 expression was lower and G6Pase expression 
      was higher in HCC compared to Meta. In particular, GLUT1 overexpression was 
      92-fold in Meta and 11-fold in HCC compared to the surrounding liver. The SUV 
      correlated with GLUT1 and PCNA expression in HCC, but not Meta patients. Of note, 
      four cases of poorly differentiated (P/D) HCC compared to moderately 
      differentiated (M/D) HCC produced completely different results for FDG uptake 
      (SUV, 14.4 vs. 4.0) and mRNA expression (G6Pase expression, 0.007 vs. 1.5). 
      Variations in the expression of glucose metabolism-related enzymes between HCC 
      and Meta patients are attributed to origin or degree of differentiation. Low FDG 
      uptake in M/D HCC reflected low GLUT1 and high G6Pase expression, while high FDG 
      accumulation in P/D HCC could reflect increased GLUT1 and decreased G6Pase 
      expression. These results may explain why M/D HCC is not detected as sensitively 
      by FDG-PET.
FAU - Izuishi, Kunihiko
AU  - Izuishi K
AD  - Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa 
      University, Miki, Kita, Kagawa 761-0793, Japan.
FAU - Yamamoto, Yuka
AU  - Yamamoto Y
AD  - Department of Radiology, Faculty of Medicine, Kagawa University, Miki, Kita, 
      Kagawa 761-0793, Japan.
FAU - Mori, Hirohito
AU  - Mori H
AD  - Department of Internal Medicine of Gastroenterology and Neurology, Faculty of 
      Medicine, Kagawa University, Miki, Kita, Kagawa 761-0793, Japan.
FAU - Kameyama, Riko
AU  - Kameyama R
AD  - Department of Radiology, Faculty of Medicine, Kagawa University, Miki, Kita, 
      Kagawa 761-0793, Japan.
FAU - Fujihara, Shintaro
AU  - Fujihara S
AD  - Department of Internal Medicine of Gastroenterology and Neurology, Faculty of 
      Medicine, Kagawa University, Miki, Kita, Kagawa 761-0793, Japan.
FAU - Masaki, Tsutomu
AU  - Masaki T
AD  - Department of Internal Medicine of Gastroenterology and Neurology, Faculty of 
      Medicine, Kagawa University, Miki, Kita, Kagawa 761-0793, Japan.
FAU - Suzuki, Yasuyuki
AU  - Suzuki Y
AD  - Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa 
      University, Miki, Kita, Kagawa 761-0793, Japan.
LA  - eng
PT  - Journal Article
DEP - 20131129
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Glucose Transporter Type 2)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (RNA, Messenger)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (SLC2A1 protein, human)
RN  - 0 (SLC2A2 protein, human)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 40871-47-4 (2-fluoro-2-deoxyglucose-6-phosphate)
RN  - 56-73-5 (Glucose-6-Phosphate)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - EC 3.1.3.9 (Glucose-6-Phosphatase)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Aged
MH  - Carcinoma, Hepatocellular/diagnosis/*diagnostic imaging/surgery
MH  - Female
MH  - *Fluorodeoxyglucose F18/chemistry
MH  - Glucose/*metabolism
MH  - Glucose Transporter Type 1/analysis/genetics
MH  - Glucose Transporter Type 2/analysis
MH  - Glucose-6-Phosphatase/genetics/metabolism
MH  - Glucose-6-Phosphate/analogs & derivatives/chemistry
MH  - Hepatectomy
MH  - Hexokinase/analysis/genetics
MH  - Humans
MH  - Liver/diagnostic imaging/metabolism/pathology
MH  - Liver Neoplasms/diagnosis/*diagnostic imaging/surgery
MH  - Male
MH  - Positron-Emission Tomography/*methods
MH  - Proliferating Cell Nuclear Antigen/genetics
MH  - RNA, Messenger/biosynthesis
MH  - Radiopharmaceuticals
EDAT- 2013/12/04 06:00
MHDA- 2014/09/04 06:00
CRDT- 2013/12/04 06:00
PHST- 2013/09/10 00:00 [received]
PHST- 2013/10/25 00:00 [accepted]
PHST- 2013/12/04 06:00 [entrez]
PHST- 2013/12/04 06:00 [pubmed]
PHST- 2014/09/04 06:00 [medline]
AID - 10.3892/or.2013.2886 [doi]
PST - ppublish
SO  - Oncol Rep. 2014 Feb;31(2):701-6. doi: 10.3892/or.2013.2886. Epub 2013 Nov 29.